Knockdown of TOR signaling pathway regulator suppresses cell migration and invasion in non‑small cell lung cancer via the regulation of epithelial‑to‑mesenchymal transition

Xu,Xiang; Zhu,Huangkai; Yang,Minglei; Zheng,Enkuo; Zhou,Yinjie; Ni,Junjun; Li,Rui; Yang,Zhenhua; He,Ti; Zhao,Guofang

doi:10.3892/etm.2019.8358

Knockdown of TOR signaling pathway regulator suppresses cell migration and invasion in non‑small cell lung cancer via the regulation of epithelial‑to‑mesenchymal transition

Authors:
- Xiang Xu
- Huangkai Zhu
- Minglei Yang
- Enkuo Zheng
- Yinjie Zhou
- Junjun Ni
- Rui Li
- Zhenhua Yang
- Ti He
- Guofang Zhao
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang 315010, P.R. China, Shanghai Genechem Translational Medicine Institute, Shanghai 200120, P.R. China
Published online on: December 20, 2019 https://doi.org/10.3892/etm.2019.8358
Pages: 1925-1932

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑small cell lung cancer (NSCLC) is one of the most common cancer types worldwide. Previous studies have indicated that TOR signaling pathway regulator (TIPRL) is involved in the progression of NSCLC. However, the underlying mechanisms of the role of TIPRL in regulating NSCLC metastasis have remained largely elusive. In the present study, the expression pattern of TIPRL in NSCLC was analyzed using The Cancer Genome Atlas (TCGA) dataset. Furthermore, Kaplan‑Meier curve analysis was performed to evaluate the prognostic value of TIPRL in NSCLC, using the Kaplan‑Meier Plotter and TCGA datasets. Loss‑of‑function assays were performed to determine the effects of TIPRL on cell migration and invasion. The results suggested that TIPRL was upregulated in NSCLC and positively associated with an advanced Tumor‑Node‑Metastasis stage. A higher expression level of TIPRL was associated with shorter overall and disease‑free survival times in patients with NSCLC. To the best of our knowledge, the present study was the first to report that TIPRL acts as a metastasis promoter in NSCLC. Silencing of TIPRL suppressed A549 cell migration and invasion. Mechanistically, the present study indicated that TIPRL knockdown significantly promoted epithelial‑cadherin expression, whereas it suppressed twist and vimentin expression in A549 cells. In conclusion, the present analysis suggested that TIPRL may serve as a biomarker for the prognosis of NSCLC and as a future target for its treatment.

View Figures

View References

1	Zhao B, Han H, Chen J, Zhang Z, Li S, Fang F, Zheng Q, Ma Y, Zhang J, Wu N and Yang Y: MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3. Cancer Lett. 342:43–51. 2014. View Article : Google Scholar : PubMed/NCBI
2	Gao L, Qiu H, Liu J, Ma Y, Feng J, Qian L, Zhang J, Liu Y and Bian T: KLF15 promotes the proliferation and metastasis of lung adenocarcinoma cells and has potential as a cancer prognostic marker. Oncotarget. 8:109952–109961. 2017. View Article : Google Scholar : PubMed/NCBI
3	Waqar SN, Samson PP, Robinson CG, Bradley J, Devarakonda S, Du L, Govindan R, Gao F, Puri V and Morgensztern D: Non-small-cell lung cancer with brain metastasis at presentation. Clin Lung Cancer. 19:e373–e379. 2018. View Article : Google Scholar : PubMed/NCBI
4	Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, Gerald WL and Massagué J: WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell. 138:51–62. 2009. View Article : Google Scholar : PubMed/NCBI
5	Jin L, Chun J, Pan C, Kumar A, Zhang G, Ha Y, Li D, Alesi GN, Kang Y, Zhou L, et al: The PLAG1-GDH1 axis promotes anoikis resistance and tumor metastasis through CamKK2-AMPK signaling in LKB1-deficient lung cancer. Mol Cell. 69:87–99 e7. 2018. View Article : Google Scholar : PubMed/NCBI
6	Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, et al: LKB1 modulates lung cancer differentiation and metastasis. Nature. 448:807–810. 2007. View Article : Google Scholar : PubMed/NCBI
7	Rosales KR, Reid MA, Yang Y, Tran TQ, Wang WI, Lowman X, Pan M and Kong M: TIPRL inhibits protein phosphatase 4 activity and promotes H2AX phosphorylation in the DNA damage response. PLoS One. 10:e01459382015. View Article : Google Scholar : PubMed/NCBI
8	Nakashima A, Tanimura-Ito K, Oshiro N, Eguchi S, Miyamoto T, Momonami A, Kamada S, Yonezawa K and Kikkawa U: A positive role of mammalian Tip41-like protein, TIPRL, in the amino-acid dependent mTORC1-signaling pathway through interaction with PP2A. FEBS Lett. 587:2924–2929. 2013. View Article : Google Scholar : PubMed/NCBI
9	Chatzimichail E, Matthaios D, Bouros D, Karakitsos P, Romanidis K, Kakolyris S, Papashinopoulos G and Rigas A: γ-H2AX: A novel prognostic marker in a prognosis prediction model of patients with early operable non-small cell lung cancer. Int J Genomics. 2014:1602362014. View Article : Google Scholar : PubMed/NCBI
10	Matthaios D, Hountis P, Karakitsos P, Bouros D and Kakolyris S: H2AX a promising biomarker for lung cancer: A review. Cancer Invest. 31:582–599. 2013. View Article : Google Scholar : PubMed/NCBI
11	Roy D, Sin SH, Lucas A, Venkataramanan R, Wang L, Eason A, Chavakula V, Hilton IB, Tamburro KM, Damania B and Dittmer DP: mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis. Cancer Res. 73:2235–2246. 2013. View Article : Google Scholar : PubMed/NCBI
12	Zhou H and Huang S: Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr Protein Pept Sci. 12:30–42. 2011. View Article : Google Scholar : PubMed/NCBI
13	Paquette M, El-Houjeiri L and Pause A: mTOR pathways in cancer and autophagy. Cancers (Basel). 10(pii): E182018. View Article : Google Scholar : PubMed/NCBI
14	Chang L, Graham PH, Ni J, Hao J, Bucci J, Cozzi PJ and Li Y: Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. Crit Rev Oncol Hematol. 96:507–517. 2015. View Article : Google Scholar : PubMed/NCBI
15	Tian L, Zhao Z, Xie L and Zhu J: MiR-361-5p suppresses chemoresistance of gastric cancer cells by targeting FOXM1 via the PI3K/Akt/mTOR pathway. Oncotarget. 9:4886–4896. 2017.PubMed/NCBI
16	Yoon JY, Lee JJ, Gu S, Jung ME, Cho HS, Lim JH, Jun SY, Ahn JH, Min JS, Choi MH, et al: Novel indazole-based small compounds enhance TRAIL-induced apoptosis by inhibiting the MKK7-TIPRL interaction in hepatocellular carcinoma. Oncotarget. 8:112610–112622. 2017. View Article : Google Scholar : PubMed/NCBI
17	Cui F, Hu J, Ning S, Tan J and Tang H: Overexpression of MCM10 promotes cell proliferation and predicts poor prognosis in prostate cancer. Prostate. 78:1299–1310. 2018. View Article : Google Scholar : PubMed/NCBI
18	Kroiss A, Vincent S, Decaussin-Petrucci M, Meugnier E, Viallet J, Ruffion A, Chalmel F, Samarut J and Allioli N: Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2. Oncogene. 34:2846–2855. 2015. View Article : Google Scholar : PubMed/NCBI
19	Park JY and Juhnn YS: cAMP signaling increases histone deacetylase 8 expression via the Epac2-Rap1A-Akt pathway in H1299 lung cancer cells. Exp Mol Med. 49:e2972017. View Article : Google Scholar : PubMed/NCBI
20	Song IS, Jun SY, Na HJ, Kim HT, Jung SY, Ha GH, Park YH, Long LZ, Yu DY, Kim JM, et al: Inhibition of MKK7-JNK by the TOR signaling pathway regulator-like protein contributes to resistance of HCC cells to TRAIL-induced apoptosis. Gastroenterology. 143:1341–1351. 2012. View Article : Google Scholar : PubMed/NCBI
21	Kundu ST, Grzeskowiak CL, Fradette JJ, Gibson LA, Rodriguez LB, Creighton CJ, Scott KL and Gibbons DL: TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins. Nat Commun. 9:27312018. View Article : Google Scholar : PubMed/NCBI
22	Grzeskowiak CL, Kundu ST, Mo X, Ivanov AA, Zagorodna O, Lu H, Chapple RH, Tsang YH, Moreno D, Mosqueda M, et al: In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer. Nat Commun. 9:27322018. View Article : Google Scholar : PubMed/NCBI
23	Brody H: Lung cancer. Nature. 513:S12014. View Article : Google Scholar : PubMed/NCBI
24	Takeyama Y, Sato M, Horio M, Hase T, Yoshida K, Yokoyama T, Nakashima H, Hashimoto N, Sekido Y, Gazdar AF, et al: Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells. Cancer Lett. 296:216–224. 2010. View Article : Google Scholar : PubMed/NCBI
25	Han J, Wang F, Lan Y, Wang J, Nie C, Liang Y, Song R, Zheng T, Pan S, Pei T, et al: KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling. Oncogene. 38:406–420. 2019. View Article : Google Scholar : PubMed/NCBI
26	Yang X, Peng Y, Jiang X, Lu X, Duan W, Zhang S, Dai N, Shan J, Feng Y, Li X, et al: The regulatory role of APE1 in epithelial-to-mesenchymal transition and in determining EGFR-TKI responsiveness in non-small-cell lung cancer. Cancer Med. 7:4406–4419. 2018. View Article : Google Scholar : PubMed/NCBI
27	Wei X, Li Q, Li Y, Duan W, Huang C, Zheng X, Sun L, Luo J, Wang D, Zhang S, et al: Prediction of survival prognosis of non-small cell lung cancer by APE1 through regulation of Epithelial-Mesenchymal Transition. Oncotarget. 7:28523–28539. 2016.PubMed/NCBI
28	Zhang Y, Zhang X, Ye M, Jing P, Xiong J, Han Z, Kong J, Li M, Lai X, Chang N, et al: FBW7 loss promotes epithelial-to-mesenchymal transition in non-small cell lung cancer through the stabilization of Snail protein. Cancer Lett. 419:75–83. 2018. View Article : Google Scholar : PubMed/NCBI